ORCID "0000-0002-5823-1704" Bildiri Koleksiyonu için listeleme
-
Are pretreatment inflammation-based prognostic scores useful in predicting the outcomes of patients with ALK-positive NSCLC?
Ölmez, Ömer Fatih; Bilici, Ahmet; Gürsoy, Pınar; Çubukçu, Erdem; Yıldız, Özcan; Sakın, Abdullah; Korkmaz, Taner; Çil, İbrahim; Çakar, Beyhan; Menekşe, Serkan; Demir, Tarık; Açıkgöz, Özgen; Hamdard, Jamshid (Elsevier Science, 2019)Background: Approximately 5% of all diagnosed non-small cell lung cancer (NSCLC) patients harbor a genetic rearrangement between the ALK and EML4 genes, representing a specific molecular and clinical subgroup (ALK+ NSCLC). ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Aydın, S. G.; Kutlu, Yasin; Açıkgöz, Özgür; Bilici, A.; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Elsevier Science Inc., 2021)Introduction: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer and in the absence of driver mutation preferred treatment is incorporation of immunotherapy.But for patients treated with chemotherapy ...